The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
898
June 11, 1993
View Complete Issue         Table of Contents 2019 
OncoScint for Detetion of Disseminated Colorectal and Ovarian Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
OncoScint for Detetion of Disseminated Colorectal and Ovarian Cancer
June 11, 1993 (Issue: 898)
Indium 111 In-satumomab pendetide (CYT-103, OncoScint CR/OV Kit - Cytogen), a new intravenous imaging agent, has been approved by the US Food and Drug Administration for detection of extrahepatic spread of colorectal and ovarian tumors.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: OncoScint for Detetion of Disseminated Colorectal and Ovarian Cancer
Article code: 898b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.